Erythropoietin in cardioprotection: Does it have a future or is it all in the past?

Cardiovascular Research

Volumn 79, Issue 4, 2008, Pages 549-550

  Mehta, Jawahar L ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

APOPTOSIS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; EDITORIAL; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYDROGEL; NONHUMAN; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANIMALS; CARDIOVASCULAR AGENTS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DRUG CARRIERS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INJECTIONS, SUBCUTANEOUS; MYOCARDIAL INFARCTION; MYOCARDIUM; SIGNAL TRANSDUCTION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 52449091879     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn176     Document Type: Editorial

References (15)

1. Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Yamaki Tet al. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res 2008;79:611- 620.
2. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. J Am Med Assoc 2005;293:90-95.
3. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-2167.
4. Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63:208-216.
5. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch WJ. Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 2007;293:H60-H68.
6. van der Meer P,, Lipsic E,, Henning RH,, Boddeus K,, van der Velden J,, Voors AA. et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-133.
7. Prunier, F., Pfister O, Hadri L, Liang L, Del Monte F, Liao R et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007;292;H522-H529.
8. Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi Y, Satoh K et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 2006;71:466-477.
9. Fujita M, Tambara K. Recent insights into human coronary collateral development. Heart 2004;90:246-450.
10. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;16:2018-2027.
11. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 2008;29:258-267.
12. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC et al. A single bolus of a long acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135- 141.
13. Belonje AM, Voors AA, van Gilst WH, Anker SD, Slart RH, Tio RA, Zijlstra F, van Veldhuisen DJ. HEBE III investigators. Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 2008;155:817- 822.
14. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J Am Med Assoc 2008;299:914-924.
15. Mitka M. New limits advised for anemia drugs. J Am Med Assoc 2008; 299:2016.